Cyclerion Therapeutics Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Regina Graul
Chief executive officer
US$874.8k
Total compensation
| CEO salary percentage | 44.68% |
| CEO tenure | 1.4yrs |
| CEO ownership | 1.7% |
| Management average tenure | no data |
| Board average tenure | 2.2yrs |
Recent management updates
Recent updates
Cyclerion stock tanks 32% on workforce reduction, clinical development refocus
Oct 06We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate
Aug 09
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate
Mar 03Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders
Oct 26Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021
Jun 21Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?
Mar 09What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?
Jan 28
Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?
Dec 20CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$3m |
| Dec 31 2024 | US$875k | US$391k | -US$3m |
| Sep 30 2024 | n/a | n/a | -US$5m |
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$11m |
| Dec 31 2023 | US$496k | US$31k | -US$13m |
Compensation vs Market: Regina's total compensation ($USD874.82K) is above average for companies of similar size in the US market ($USD645.80K).
Compensation vs Earnings: Regina's compensation has increased whilst the company is unprofitable.
CEO
Regina Graul (47 yo)
Dr. Regina M. Graul, Ph.D. is President of Cyclerion Therapeutics, Inc. from December 01, 2023 and also serves as its Chief Executive Officer and Director since August 2024. Dr. Graul joined Cyclerion on D...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$874.82k | 1.74% $ 181.3k | |
| Director | 6.1yrs | US$12.00k | 17.42% $ 1.8m | |
| Independent Chairman | 4.1yrs | US$30.00k | 1.56% $ 162.5k | |
| Independent Director | 2.8yrs | US$12.00k | 0.62% $ 65.0k | |
| Independent Director | 1.5yrs | US$12.00k | 0% $ 0 | |
| Independent Director | 1.4yrs | US$12.00k | 0.62% $ 65.0k |
Experienced Board: CYCN's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 19:56 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cyclerion Therapeutics, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pete Stavropoulos | Cantor Fitzgerald & Co. |
| Martin Auster | Credit Suisse |
| Joon So Lee | Truist Securities |